1. Thanikachalam, K, Khan, G. Colorectal cancer and nutrition. Nutrients 2019; 11(1): 164.
Google Scholar | Crossref2. Tsoi, KKF, Hirai, HW, Chan, FCH, et al. Predicted increases in incidence of colorectal cancer in developed and developing regions, in association with ageing populations. Clin Gastroenterol Hepatol 2017; 15(6): 892–900.e4.
Google Scholar | Crossref | Medline3. Haller, DG, Tabernero, J, Maroun, J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29(11): 1465–1471.
Google Scholar | Crossref | Medline | ISI4. Sui, X, Chen, R, Wang, Z, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013; 4(10): e838.
Google Scholar | Crossref | Medline5. Chen, W, Zheng, R, Baade, PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115–132.
Google Scholar | Crossref | Medline | ISI6. Palma, S, Zwenger, AO, Croce, MV, et al. From molecular biology to clinical trials: toward personalized colorectal cancer therapy. Clin Colorectal Cancer 2016; 15(2): 104–115.
Google Scholar | Crossref | Medline7. Woo, IS, Jung, YH. Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett 2017; 400: 319–324.
Google Scholar | Crossref | Medline8. Bregoli, L, Movia, D, Gavigan-Imedio, JD, et al. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine 2016; 12(1): 81–103.
Google Scholar | Crossref | Medline9. He, C, Tang, Z, Tian, H, et al. Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv Drug Deliv Rev 2016; 98: 64–76.
Google Scholar | Crossref | Medline10. Xu, Z, Chan, HM, Li, C, et al. Synthesis, structure, and cytotoxicity of oxaliplatin-based platinum(IV) anticancer prodrugs bearing one axial fluoride. Inorg Chem 2018; 57(14): 8227–8235.
Google Scholar | Crossref | Medline11. Omar, S, Lemonnier, B, Jones, N, et al. Antimicrobial activity of extracts of eastern North American hardwood trees and relation to traditional medicine. J Ethnopharmacol 2000; 73(1–2): 161–170.
Google Scholar | Crossref | Medline12. Lu, KP, Zhou, XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007; 8(11): 904–916.
Google Scholar | Crossref | Medline | ISI13. Fila, C, Metz, C, van der Sluijs, P. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J Biol Chem 2008; 283(31): 21714–21724.
Google Scholar | Crossref | Medline14. Neri, I, Bianchi, F, Giacomini, F, et al. Acute irritant contact dermatitis due to Juglans regia. Contact Dermatitis 2006; 55(1): 62–63.
Google Scholar | Crossref | Medline15. Yeh, ES, Means, AR. PIN1, the cell cycle and cancer. Nat Rev Cancer 2007; 7(5): 381–388.
Google Scholar | Crossref | Medline16. Aithal, BK, Sunil Kumar, MR, Rao, BN, et al. Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes. J Pharm Sci 2011; 100(8): 3517–3528.
Google Scholar | Crossref | Medline17. Riddell, IA . Cisplatin and oxaliplatin: our current understanding of their actions. Met Ions Life Sci, 18 2018: 18.
Google Scholar18. Hu, C-MJ, Zhang, L, Aryal, S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A 2011; 108(27): 10980–10985.
Google Scholar | Crossref | Medline19. Aryal, S, Hu, C-MJ, Fang, RH, et al. Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (Lond) 2013; 8(8): 1271–1280.
Google Scholar | Crossref | Medline20. Piao, J-G, Wang, L, Gao, F, et al. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 2014; 8(10): 10414–10425.
Google Scholar | Crossref | Medline21. Guo, Y, Wang, D, Song, Q, et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 2015; 9(7): 6918–6933.
Google Scholar | Crossref | Medline22. Fang, RH, Hu, C-MJ, Zhang, L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther 2012; 12(4): 385–389.
Google Scholar | Crossref | Medline23. Rao, L, Bu, L-L, Xu, J-H, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small 2015; 11(46): 6225–6236.
Google Scholar | Crossref | Medline24. Luk, BT, Fang, RH, Hu, C-MJ, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 2016; 6(7): 1004–1011.
Google Scholar | Crossref | Medline25. Rao, L, Xu, J-H, Cai, B, et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology 2016; 27(8): 085106.
Google Scholar | Crossref | Medline26. Luk, BT, Hu, CM, Fang, RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014; 6(5): 2730–2737.
Google Scholar | Crossref | Medline27. BHATERIA, M, RACHUMALLU, R, SINGH, R, et al. Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies. Expert Opin Drug Delivery 2014; 11(8): 1219–1236.
Google Scholar | Crossref | Medline28. ZARRIN, A, FOROOZESH, M, HAMIDI, M. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin Drug Delivery 2014; 11(3): 433–447.
Google Scholar | Crossref | Medline29. Usman, WM, Pham, TC, Kwok, YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun 2018; 9(1): 2359–2366.
Google Scholar | Crossref | Medline30. Fu, X, Yang, Y, Li, X, et al. RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine 2016; 12(6): 1627–1639.
Google Scholar | Crossref | Medline31. Teesalu, T, Sugahara, KN, Ruoslahti, E. Tumor-penetrating peptides. Front Oncol 2013; 3: 216.
Google Scholar | Crossref | Medline32. Sugahara, KN, Teesalu, T, Karmali, PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010; 328(5981): 1031–1035.
Google Scholar | Crossref | Medline33. Ma, L, Chen, Q, Ma, P, et al. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery. Nanomedicine (Lond) 2017; 12(16): 1991–2006.
Google Scholar | Crossref | Medline34. Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell 2000; 100(1): 57–70.
Google Scholar | Crossref | Medline | ISI35. Teesalu, T, Sugahara, KN, Kotamraju, VR, Ruoslahti, E, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 2009; 106(38): 16157–16162.
Google Scholar | Crossref | Medline36. Parikh, AA, Fan, F, Liu, WB, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004; 164(6): 2139–2151.
Google Scholar | Crossref | Medline37. Yu, DC, Waby, JS, Chirakkal, H, et al. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol Cancer 2010; 9: 276.
Google Scholar | Crossref | Medline | ISI38. Kadonosono, T, Yamano, A, Goto, T, et al. Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation. J Control Release 2015; 201: 14–21.
Google Scholar | Crossref | Medline39. Haspel, N, Zanuy, D, Nussinov, R, et al. Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach. Biochemistry 2011; 50(10): 1755–1762.
Google Scholar | Crossref | Medline40. Ding, N, Zou, Z, Sha, H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun 2019; 10(1): 1336.
Google Scholar | Crossref | Medline41. Jaya, Agnihotri, Narendra, Kumar Jain. Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine. Artif Cells Nanomed Biotechnol 2013; 41(5): 309–314.
Google Scholar | Crossref | Medline42. Bhateria, M, Rachumallu, R, Singh, R, et al. Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies. Expert Opin Drug Deliv 2014; 11(8): 1219–1236.
Google Scholar | Crossref | Medline43. Zarrin, A, Foroozesh, M, Hamidi, M. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin Drug Deliv 2014; 11(3): 433–447.
Google Scholar | Crossref | Medline44. Hu, C-MJ, Fang, RH, Luk, BT, et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 2013; 5(7): 2664–2668.
Google Scholar | Crossref | Medline45. Gupta, N, Patel, B, Ahsan, F. Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm Res 2014; 31(6): 1553–1565.
Google Scholar | Crossref | Medline46. Sugahara, KN, Teesalu, T, Karmali, PP, et al Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16(6): 510–520.
Google Scholar | Crossref | Medline | ISI47. Liu, X, Lin, P, Perrett, I, et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest 2017; 127(5): 2007–2018.
Google Scholar | Crossref | Medline48. Wang, Y, Xie, Y, Li, J, et al. Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy. ACS Nano 2017; 11(2): 2227–2238.
Google Scholar | Crossref | Medline49. Luk, BT, Zhang, L. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release 2015; 220(Pt B): 600–607.
Google Scholar | Crossref | Medline | ISI